TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03248492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8201a
Description: DS-8201a is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered as low, medium and high intravenous (IV) doses for Part 1 of the trial. The dose for Part 2 will be determined based on results from Part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8201a
Description: DS-8201a is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered as low, medium and high intravenous (IV) doses for Part 1 of the trial. The dose for Part 2 will be determined based on results from Part 1.

Intervention type: DRUG
Group type: OTHER
Intervention: DS-8201a
Description: DS-8201a is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered as low, medium and high intravenous (IV) doses for Part 1 of the trial. The dose for Part 2 will be determined based on results from Part 1.
Study: NCT03023501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Study: NCT02424825

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cooking Course
Description: This is a month-long online cooking course, aimed at promoting a low-fat, plant-based diet.
Study: NCT00935818

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: varenicline - 1 mg bid for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Varenicline
Description: varenicline - 1 mg bid for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupropion SR
Description: bupropion sr - 150 mg bid for 12 weeks
Study: NCT01831479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Single administration of rosuvastatin 20mg tablet QD for 7 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan
Description: Single administration of olmesartan 40mg tablet QD for 7 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin and olmesartan
Description: Co-administration of rosuvastatin 20mg tablet and and olmesartan 40mg tablet QD for 7 consecutive days
Study: NCT03799835

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BCG
Description: Intravesical administration OncoTice wil be used only under two conditions : BCG Medac® unavailable and the patient has received at minimum one instillation of BCG Medac®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCG
Description: Intravesical administration OncoTice wil be used only under two conditions : BCG Medac® unavailable and the patient has received at minimum one instillation of BCG Medac®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: IV perfusion
Study: NCT00684619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelarabine
Description: 1500 mg/m² i.v., duration 2 hrs, day 1, 3, 5
Study: NCT01055301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: microarray analysis
Study: NCT05024448

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: oral administration, 60mg/d for 10d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: oral administration, 60mg/d for 10d
Study: NCT01055301

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous-autologous tandem hematopoietic stem cell transplantation
Study: NCT02549105

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMLA CREAM 5 mg
Description: EMLA CREAM APPLICATION FOR WOUND AFTER CS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LIDOCAINE 1 %
Description: LIDOCAINE 1 % INFILTERATION FOR WOUND AND ASSESSMENT OF PAIN IN FIRST 6 HOURS
Study: NCT03222804

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium
Description: Each B. infantis (strain: BIEVC001) dose will be provided in one 625 mg sachet delivering 156 mg of live bacteria at a dose of 9x10\^9 CFU plus 469 mg of pharmaceutical-grade lactose as the excipient and dispensed to participants by the study personnel.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium
Description: Each B. infantis (strain: BIEVC001) dose will be provided in one 625 mg sachet delivering 156 mg of live bacteria at a dose of 9x10\^9 CFU plus 469 mg of pharmaceutical-grade lactose as the excipient and dispensed to participants by the study personnel.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium
Description: Each B. infantis (strain: BIEVC001) dose will be provided in one 625 mg sachet delivering 156 mg of live bacteria at a dose of 9x10\^9 CFU plus 469 mg of pharmaceutical-grade lactose as the excipient and dispensed to participants by the study personnel.
Study: NCT02789501

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 4% citrate lock solution regimen
Description: (CitraFlow™ 4%, MedXL, Montreal, Canada) will be injected in each of the 2 lumens of the tunneled catheters after each dialysis session (2ml/lumen, 3x/week).
Study: NCT00762736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone and azilsartan
Description: Pioglitazone 15 mg, tablets, orally, once daily and azilsartan 5 mg, tablets, orally, once daily for up to 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone and azilsartan
Description: Pioglitazone 15 mg, tablets, orally, once daily and azilsartan 40 mg, tablets, orally, once daily for up to 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone 15 mg, tablets, orally, once daily and azilsartan placebo-matching tablets, orally, once daily for up to 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone and azilsartan
Description: Pioglitazone 45 mg, tablets, orally, once daily and azilsartan 5 mg, tablets, orally, once daily for up to 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone and azilsartan
Description: Pioglitazone 45 mg, tablets, orally, once daily and azilsartan 40 mg, tablets, orally, once daily for up to 24 weeks.
Study: NCT02789501

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TauroLock lock solution regimen
Description: After the first two dialysis sessions of the week (before the short intervals) 2 ml of TauroLock™-Hep500 containing 1% (cyclo)-taurolidine, 4% citrate and 500 IU/mL heparin will be injected into each of the two lumens of the tunneled catheter. After the third dialysis of the week, thus before the long interval, 2 ml of TauroLock™-U25.000 which contains 1% (cyclo)-taurolidine, 4% citrate and 25.000 IU urokinase will be applied into each lumen.
Study: NCT01198405

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enhanced external counterpulsation
Description: Treatment of enhanced external counterpulsation (EECP) with a prespecified protocol on top of a guideline-driven standard medical therapy. EECP Protocol is defined as a standard session of a total of 36 hours of EECP treatment, given one hour per day, six days per week. The same session is thereafter repeated at least once every year.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guideline-driven standard medical therapy
Description: Standard management, both pharmacological and non-pharmacological, given according to current practice guidelines at the discretion of clinicians
Study: NCT02995993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moss-aGal (recombinant human alpha-galactosidase A produced in moss)
Description: Single i.v. Infusion of 0.2 mg/kg moss-aGal over 60 minutes
Study: NCT03885947

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cord blood stem cells
Description: CD34 selected VPA expanded umbilical cord blood cells used in combination with or without unmanipulated umbilical cord blood .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: Valproic Acid (VPA) expanded cord blood stem cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 150 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytoxan
Description: Cytoxan 50 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Thiotepa 10 mg/m2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TBI
Description: TBI 400cGy
Study: NCT00643201

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: solution, subcutaneous, 1 mg/kg Q12h until International normalized ratio (INR) ≥2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: warfarin
Description: tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for apixaban
Description: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by placebo for apixaban 5 mg tablets, twice daily, 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for enoxaparin
Description: solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for warfarin
Description: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apixaban
Description: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months
Study: NCT03850626

Intervention type: BIOLOGICAL
Intervention: Immunotherapy
Description: subcutaneous injection

Intervention type: BIOLOGICAL
Intervention: Immunotherapy
Description: subcutaneous injection

Intervention type: BIOLOGICAL
Intervention: Immunotherapy
Description: subcutaneous injection
Study: NCT02766543

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI-guided Transurethral Ultrasound Ablation
Description: Magnetic resonance imaging-guided transurethral ultrasound ablation is a novel minimally-invasive procedure where the therapeutic endpoint is prostate ablation through thermal coagulation.
Study: NCT01228006

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NatusGerin
Description: 1 capsule, 2 times a day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: 1 capsule, 2 times a day
Study: NCT01596569

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Daily rTMS treatment for one week. Sham TMS participants receive the same study procedures as patients receiving active TMS.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Daily rTMS treatment for one week. Sham TMS participants receive the same study procedures as patients receiving active TMS.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Intervention
Description: Cognitive intervention designed specifically to address the most common cognitive deficits (executive function and memory) in bTBI.~All participants receive weekly cognitive treatment sessions for 10 weeks.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cognitive Intervention
Description: Cognitive intervention designed specifically to address the most common cognitive deficits (executive function and memory) in bTBI.~All participants receive weekly cognitive treatment sessions for 10 weeks.
Study: NCT01911832

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: esophagojejunostomy after total gastrectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastrojejunostomy after subtotal gastrectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: wide tube reconstruction after subtotal gastrectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: narrow tube reconstruction after subtotal gastrectomy
Study: NCT02018133

Intervention type: DRUG
Intervention: Vitamin D 2mg daily for 2 weeks oral paricalcitol
Description: vitamin D 2 capsules daily

Intervention type: DRUG
Intervention: Placebo
Description: placebo 2 capsule daily
Study: NCT02089477

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Support group
Description: The participants in the intervention group receives the intervention and support consisting of:~1. Individual Goal Setting: 2-3 functional goals related to everyday life evaluated every 4th week.~2. SMS send every Sunday with 5 possible responses. depending on the answer of the participant it will cause a telephone call from a project about motivation and barriers for interval walking.
Study: NCT04275336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMLA application
Description: A thick layer of cream (lidocaine and propiocaine 2.5%/2.5%) will be applied on a 1x1 cm2 area of skin on the cannulation site. The transparent dressing will be left in place for 30 minutes, then remove and clean with a sterile cotton swab. Then nurse perform IV cannulation for them.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distraction techniques
Description: Multiple distractions including toy whistles, cartoon books, a TV showing cartoons, and various electronic products with video games will be provided for the children to choose and play with. They will also be taught breathing exercises (i.e. inhaling through the nose for 3 seconds and exhaling for 5 seconds, while they are counting) if they are willing. A play therapist play with the children for 5 min. prior to and throughout the venipuncture procedure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMLA cream and distraction techniques
Description: both EMLA cream and distraction techniques will be used. EMLA cream will be applied on the pre-puncture site for 30 minutes as the EMLA group, then 5 minutes before the venipuncture, the play therapist encourage them to choose their favorite toys to play with or to learn breathing exercises. During IV cannulation the play therapist will also continue distracting the child with toys.
Study: NCT04458896

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stand When You Can
Description: Intervention strategies can be customized to different environments based on consultation with management. Some strategies will be mandatory:~* Education session: group information session during the first week of the intervention (30min) to discuss sedentary time (ST), health risks, strategies to reduce ST, goal setting, \& the identification of barriers and motivators to reducing ST. Group discussion will be encouraged to increase self-motivation and self-efficacy. An information workbook will be given to each attendee for their personal use and goal setting.~* Point of decision prompts (ie: signs that encourage standing; see attachments) will be placed in common areas of the facility, and/or given as pamphlets to residents.~* An intervention package will be provided to the Activity Coordinator and Manager of the facility. This package will provide an introductory letter along with materials to promote reduced sedentary time in the facility
Study: NCT03289338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: Zoledronic acid 5mg intravenous once a month for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Methylprednisolone 1gm intravenous once a month for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Normal saline intravenous once a month for 3 months
Study: NCT00762736

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone 45 mg, tablets, orally, once daily and azilsartan placebo-matching tablets, orally, once daily for up to 24 weeks.
Study: NCT00967031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: circulating tumor cell analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study: NCT01588132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anfibatide
Description: 1. To investigate the safety and tolerability of single intravenous dose of Antiplatelet Thrombolysin for Injection of 0.33,0.66,1.0,1.5,2.0,3.0,4.0,5.0μg (body weight 60kg) in healthy volunteers.~2. To investigate the safety and tolerability of continuous administration of three dose regimen: ① give intravenous injection of 3μg as the first dose and after 1.5 hours, infusion of the study product 0.12μg/h for 24 hours. ② give intravenous injection of 3μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours. ③ give intravenous injection of 5μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anfibatide
Description: 1. To investigate the safety and tolerability of single intravenous dose of Antiplatelet Thrombolysin for Injection of 0.33,0.66,1.0,1.5,2.0,3.0,4.0,5.0μg (body weight 60kg) in healthy volunteers.~2. To investigate the safety and tolerability of continuous administration of three dose regimen: ① give intravenous injection of 3μg as the first dose and after 1.5 hours, infusion of the study product 0.12μg/h for 24 hours. ② give intravenous injection of 3μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours. ③ give intravenous injection of 5μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours.
Study: NCT03588273

Intervention type: DRUG
Group type: OTHER
Intervention: Amoxil 500 MG Oral Capsule
Study: NCT03027947

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulator
Description: Spinal cord stimulator leads (2-3 leads) will be placed in the lumbar epidural space of lower limb amputees to determine if the patient experiences any pain reduction from spinal cord stimulation.
Study: NCT03757416

Intervention type: OTHER
Intervention: Data collection
Description: If it has been determined that the patient will be undergoing flexor tenosynovectomy for the treatment of recurrent carpal tunnel syndrome, the patient will be asked to participate in this data collection study.
Study: NCT02696889

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ROSE-1 Protocol
Description: A bone marrow aspiration will be performed under anesthesia in preparation for a diagnostic laparoscopy for full evaluation of the pelvic anatomy. Following laparoscopy, injection of BMSCs into the right ovary will occur.
Study: NCT04517682

Intervention type: DIAGNOSTIC_TEST
Intervention: RT-PCR
Description: The RT-PCR assay will be performed on paired nasopharyngeal and saliva samples

Intervention type: DIAGNOSTIC_TEST
Intervention: RT-PCR
Description: The RT-PCR assay will be performed on paired nasopharyngeal and saliva samples
Study: NCT01042626

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral peptones load
Description: Enrolled subjects will receive 10 g Liebig meat extract diluted in 250ml of 0.9% saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral peptones load
Description: Enrolled subjects will receive 10 g Liebig meat extract diluted in 250ml of 0.9% saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral peptones load
Description: Enrolled subjects will receive 10 g Liebig meat extract diluted in 250ml of 0.9% saline
Study: NCT01178294

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OBI-1
Description: Intravenous infusion
Study: NCT00773617

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICAT
Description: ICAT is a new manual-based psychotherapy treatment for bulimia nervosa (BN) that focuses on emotions and bulimic behavior.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Description: CBT is a highly structured, manual-based psychotherapy that has been shown to be effective in the treatment of BN. CBT focuses on cognitions and bulimic behavior.
Study: NCT02953730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Study: NCT02783066

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Offloading boot: PulseFlow
Description: A new offloading boot, which may enhance balance, gait, and lower extremity blood flow
Study: NCT02948816

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facebook
Description: Participants will spend 30 minutes on a Facebook page that is primarily non-food related posts.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facebook + Food
Description: Participants will spend 30 minutes on a Facebook page that is food related posts.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Colouring
Description: Participants will spend 30 minutes colouring quietly.
Study: NCT02135952

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SRP
Description: SRP in four to six appointments lasting approximately 1 h each, using manual curettes and ultrasonic device under local anesthesia.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: SRP
Description: SRP in four to six appointments lasting approximately 1 h each, using manual curettes and ultrasonic device under local anesthesia.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo for 14 days started immediately after the first session of SRP.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTZ+AMX
Description: Administration of antibiotics (metronidazole and amoxicillin) for 14 days started immediately after the first session of SRP.
Study: NCT03211065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20% subcutaneous immunoglobulin
Description: Subcutaneous Immunoglobulin